Abstract:Background and Aims The increasingly widespread of immune checkpoint inhibitors (ICIs) in the field of antitumors has brought a new dawn for patients with advanced biliary tract cancer (aBTC). However, the choice of treatment needs to be supported by economic evaluation. Therefore, the cost‐effectiveness comparison of first‐line durvalumab or pembrolizumab plus gemcitabine and cisplatin (GemCis) treatment of aBTC was explored from the perspective of American and Chinese healthcare systems. Methods Ground on the TOPAZ‐1 and KEYNOTE‐966 trials, the Markov model with a 15‐year horizon including three health states to imitate cost and effective outcomes was established. Incremental cost‐effectiveness ratio (ICER) at willingness‐to‐pay (WTP) thresholds of 37 408/ALY in the USA and China was used as the most important indicator. Other endpoint indexes included total cost, life years (LYs), quality‐adjusted life years (QALYs) and incremental net‐health benefit (INHB). To verify the robustness, sensitivity and subgroup analyses were performed. Results Durvalumab plus GemCis ( 35 695 [2.76 QALYs]) increased cost (effectiveness) by 5234 (.20 QALYs) than pembrolizumab plus GemCis ( 30 461 [2.56 QALYs]) in the USA and China, respectively. The corresponding ICER was 26 401/QALY, with INHB of −.42 and .06 QALYs, respectively. The cost of ICIs was the most important factor influencing results. Conclusions In China, first‐line durvalumab plus GemCis versus pembrolizumab plus GemCis was a cost‐effective option for patients with aBTC, but not in the USA.

Immune checkpoint inhibitor for patients with advanced biliary tract cancer: A cost‐effectiveness analysis